Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Ny OMF-finansiert Forsknings Publikasjon: En Nanoelektronisk-blodbasert diagnostisk biomarkør for ME / CFS

 

 

Dr. Ron Davis, OMF Scientific Advisory Board Director, forklarer PNAS publikasjonen om nanoneedle’en. (29.april, 2019)

Les denne artikkelen på Facebook

Les denne artikkelen på OMFs nettside

Les alle oversettelser av denne og andre artikler på OMFs nettside

Et paper som beskriver nanoneedlen ble publisert i Proceedings of the National Academy of Sciences (PNAS). Ronald W. Davis, PhD, er seniorforfatteren. Rahim Esfandyarpour, PhD, er hovedforfatteren. Nanoneedlen er en test som måler endringer i immunceller med blodplasma som følge av saltstress. Inne i nanoneedlen forstyrrer immuncellene en liten elektrisk strøm. Endringer i den elektriske aktiviteten er direkte korrelert med helsen til prøven. Testen, som fremdeles er i pilotfasen, er basert på hvordan en persons immunceller reagerer på stress. Med blodprøver fra 40 personer – 20 med ME / CFS og 20 uten – ga testen nøyaktige resultater, og flagget alle pasientene og ingen av de friske individene.

 

klikk her for å se videoen

 

Klikk her for å lese sammendraget og den fulle publikasjonen på PNAS.

 

Klikk her for å lese Stanford kunngjøringen.

 

OMF takker Beathe Lindseth for denne oversettelsen.

 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo